News

Funding is in the form of one SBIR Phase 1 award titled ‘effects of P-188 on respiratory function and diaphragm degeneration in the mdx mouse’ and STTR phase

Rivaroxaban is a novel oral anticoagulant being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. Rivaroxaban

The experts at the Adaptive Clinical Trials Innovation Center work with clients to assist with the trial design, simulation and execution, develop adaptive trials software tools, and work

Under the agreement, OBT will use Potelligent Technology for the manufacturing, development and commercializing chosen ADCC programs from its pipeline of preclinical antibodies for oncology, which it has

The two programs were part of Sunesis multi-kinase inhibitor collaboration with Biogen Idec, which was signed in 2004. Further in 2010, Biogen Idec has out licensed all its

GliaMed will be eligible to receive up to 8,205 shares of newly designated Series E Preferred Stock, which would be convertible into approximately 20% of the company’s fully

The single-arm screening Phase 2 trial is being conducted at seven centres across Canada and will enroll up to 30 patients whose brain tumour is in first relapse

The study is designed to determine the safety and pharmacokinetics of multiple ascending oral doses of DB959Na in both male and female subjects. The study results are estimated

Phoenix is a PK/PD modeling software platform that includes a range of tools that can be used individually or together. Pharsight claims the advanced Phoenix will support Windows